EVolution Therapeutics Secures £284,000 Innovate UK Grant Through ICURe Programme

We are delighted to announce that EVolution Therapeutics has secured a £284,000 Innovate UK grant to develop an advanced wound care therapeutic for the treatment of non-healing wounds. This funding was secured through participation in the BBSRC/Innovate UK innovation to commercialisation of university research (ICURe) programme. ICURe serves as the “UK’s leading early-stage research pre-accelerator programme, guiding researchers through the process of validating commercial potential”.


Addressing a Global Medical Challenge: Non-Healing Wounds

One of the most pressing medical challenges worldwide is the treatment of non-healing wounds. At EVolution Therapeutics, we recognize the urgency of this issue, and we are committed to making a significant impact. Currently, the therapeutic options for wound healing are limited in scope, leading to a substantial burden on healthcare systems globally. For instance, in 2018, the management of non-healing wounds alone cost the NHS a staggering £5.6 billion, involving a resource draining 54 million community nurse visits. Despite these efforts, the problem continues to increase at pace and patient quality of life remains alarmingly poor.

Now, with the support of the £284,000 Innovate UK grant secured through ICURe, EVolution Therapeutics will develop an extracellular vesicle/nanoparticle based therapy which actively accelerates wound healing. It stands in stark contrast to current anti-inflammatory and passive wound management treatments currently available. Our mission is clear: to transform the treatment of inflammatory diseases and enhance the lives of patients worldwide.